PharmAla Biotech Provides Corporate Update: Change of Auditor, Retention of Watertower Research and Oak Hill

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today announced three corporate updates. 1. Change of Auditor: The Company determined that it was in its […]